CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Bortezomib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00839956
NCT00839956Phase 2Completed
CompareCT.gov

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma

Fred Hutchinson Cancer Center·interventional·Posted Feb 10, 2009·Updated May 9, 2017

In Brief

A Phase 2 clinical trial evaluating Bortezomib and Vorinostat for DS Stage I Plasma Cell Myeloma and 2 related conditions. Completed, enrolled 31 participants across 1 site.

Detailed Summary

This phase II trial studies the side effects of giving bortezomib together with vorinostat and to see how well it works in treating patients with multiple myeloma who have undergone autologous stem cell transplant. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat after an autologous stem cell transplant may stop the growth of any cancer cells that remain after transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 10, 2009
Enrollment StartFeb 1, 2009
Primary CompletionAug 1, 2012
Study CompletionMar 31, 2017
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 17.4 years ago

Interventions

Bortezomibdrug

Given IV

Vorinostatdrug

Given PO